Exposure to the selective κ-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats (Neuropsychopharmacology (2008) (7) DOI: 10.1038/sj.npp.1301659);Exposure to the selective κ-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats

Neuropsychopharmacology

Volumn 33, Issue 11, 2008, Pages 2676-2687

  Chartoff, Elena H ^a   Potter, David ^a   Damez Werno, Diane ^a   Cohen, Bruce M ^a   Carlezon Jr , William A ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

c Fos; D1 receptor; Dopamine; Dynorphin; Locomotor activity; Striatum

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; COCAINE; DYNORPHIN; KAPPA OPIATE RECEPTOR AGONIST; PROTEIN C FOS; SALVINORIN A;

ARTICLE; BEHAVIOR; BRAIN REGION; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIZATION; LOCOMOTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULUS RESPONSE;

EID: 51749123754     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.63     Document Type: Erratum

References (69)

1. Arvidsson U, Riedl M, Chakrabarti S, Vulchanova L, Lee JH, Nakano AH et al (1995). The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc Natl Acad Sci USA 92: 5062-5066.
2. Badiani A, Anagnostaras SG, Robinson TE (1995). The development of sensitization to the psychomotor stimulant effects of amphetamine is enhanced in a novel environment. Psychopharmacology (Berl) 117: 443-452.
3. Badiani A, Oates MM, Day HEW, Watson SJ, Akil H, Robinson TE (1998). Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty. J Neurosci 18: 10579-10593.
4. Badiani A, Robinson TE (2004). Drug-induced neurobehavioral plasticity: the role of environmental context. Behav Pharmacol 15: 327-339.
5. Barrett JE (ed) (1987). Nonpharmacological Factors Determining the Behavioral Effects of Drugs. Raven: New York, pp 1493-1501.
6. Carlezon Jr WA, Beguin C, Dinieri JA, Baumann MH, Richards MR, Todtenkopf MS et al (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
7. Chavkin C, James IF, Goldstein A (1982). Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215: 413-415.
8. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ et al (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203.
9. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS (2005). Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25: 5029-5037.
10. Chieng BC, Christie MJ, Osborne PB (2006). Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology, and opioid sensitivity. J Comp Neurol 497: 910-927.
11. Cohen BM, Murphy B (2007). The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol 1-5. (E-pub ahead of print 26 September 2007).
12. Covington III HE, Miczek KA (2001). Repeated social-defeat stress, cocaine or morphine. Effects on behavioral sensitization and intravenous cocaine self-administration 'binges'. Psychopharmacology (Berl) 158: 388-398.
13. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
14. Erb S, Shaham Y, Stewart J (1996). Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 128: 408-412.
15. Falk JL, Feingold DA (eds). (1987). Environmental and Cultural Factors in the Behavioral Actions of Drugs. Raven: New York, pp 1503-1510.
16. Goussakov I, Chartoff EH, Tsvetkov E, Gerety LP, Meloni EG, Carlezon Jr WA et al (2006). LTP in the lateral amygdala during cocaine withdrawal. Eur J Neurosci 23: 239-250.
17. Gray AM, Rawls SM, Shippenberg TS, McGinty JF (1999). The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem 73: 1066-1074.
18. Harlan RE, Garcia MM (1998). Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 16: 221-267.
19. Heidbreder CA, Babovic-Vuksanovic D, Shoaib M, Shippenberg TS (1995). Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. J Pharmacol Exp Ther 275: 150-163.
20. Heidbreder CA, Schenk S, Partridge B, Shippenberg TS (1998). Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 30: 255-262.
21. Herman JP, Stinus L, Le Moal M (1984). Repeated stress increases locomotor response to amphetamine. Psychopharmacology (Berl) 84: 431-435.
22. Hjelmstad GO, Fields HL (2003). Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol 89: 2389-2395.
23. Hurd YL, Brown EE, Finlay JM, Fibiger HC, Gerfen CR (1992). Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res Mol Brain Res 13: 165-170.
24. Izenwasser S, Acri JB, Kunko PM, Shippenberg T (1998). Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse 30: 275-283.
25. Kessler RC (1997). The effects of stressful life events on depression. Annu Rev Psychol 48: 191-214.
26. Kiyatkin EA (1992). State-dependent peculiarities of cocaine-induced behavioral sensitization and their possible reasons. Int J Neurosci 67: 93-103.
27. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
28. Koob GF, Stinus L, Le Moal M, Bloom FE (1989). Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev 13: 135-140.
29. Kuzmin AV, Gerrits M, Van Ree JM (1998). kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats. Eur J Pharmacol 358: 197-202.
30. Lee DY, Ma Z, Liu-Chen LY, Wang Y, Chen Y, Carlezon Jr WA et al (2005). New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem 13: 5635-5639.
31. Lu L, Shepard JD, Scott Hall F, Shaham Y (2003). Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. Neurosci Biobehav Rev 27: 457-491.
32. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H et al (1994). Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350: 412-438.
33. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL (2006). Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 103: 2938-2942.
34. Markou A, Kosten TR, Koob GF (1998). Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18: 135-174.
35. McDaniel KL, Mundy WR, Tilson HA (1990). Microinjection of dynorphin into the hippocampus impairs spatial-learning in rats. Pharmacol Biochem Behav 35: 429-435.
36. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C (2006). Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 31: 787-794.
37. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
38. McLaughlin JP, Myers LC, Zarek PE, Caron MG, Lefkowitz RJ, Czyzyk TA et al (2004). Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem 279: 1810-1818.
39. Mello NK, Negus SS (2000). Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci 909: 104-132.
40. Meshul CK, McGinty JF (2000). Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96: 91-99.
41. Morgan JI, Curran T (1991). Stimulus-transcription coupling in the nervous-system - involvement of the inducible protooncogenes Fos and Jun. Annu Rev Neurosci 14: 421-451.
42. Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F (2005). Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem 48: 345-348.
43. Negus SS (2004). Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) 176: 204-213.
44. Negus SS, Mello NK, Portoghese PS, Lin CE (1997). Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.
45. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
46. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986). Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776.
47. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
48. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247-291.
49. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S et al (2002). Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99: 11934-11939.
50. Schenk S, Partridge B, Shippenberg TS (1999). U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144: 339-346.
51. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
52. Sheng M, McFadden G, Greenberg ME (1990). Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 4: 571-582.
53. Shippenberg TS, Herz A (1988). Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 151: 233-242.
54. Shippenberg TS, LeFevour A, Heidbreder C (1996). kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276: 545-554.
55. Shippenberg TS, Rea W (1997). Sensitization to the behavioral effects of cocaine: modulation by dynorphin and kappa-opioid receptor agonists. Pharmacol Biochem Behav 57: 449-455.
56. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS (2004). Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90: 1258-1268.
57. Siebert DJ (1994). Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43: 53-56.
58. Sinha R, Catapano D, O'Malley S (1999). Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology Berl) 142: 343-351.
59. Smiley PL, Johnson M, Bush L, Gibb JW, Hanson GR (1990). Effects of cocaine on extrapyramidal and limbic dynorphin systems. J Pharmacol Exp Ther 253: 938-943.
60. Spanagel R, Herz A, Shippenberg TS (1992). Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046-2050.
61. Spangler R, Unterwald EM, Kreek MJ (1993). 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res Mol Brain Res 19: 323-327.
62. Svingos AL, Colago EE, Pickel VM (1999). Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci 19: 1804-1813.
63. Thompson AC, Zapata A, Justice Jr JB, Vaughan RA, Sharpe LG, Shippenberg TS (2000). Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20: 9333-9340.
64. Todtenkopf MS, Carlezon Jr WA (2006). Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization. Psychopharmacology (Berl) 185: 451-458.
65. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon Jr WA (2004). Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 172: 463-470.
66. Unterwald EM, Knapp C, Zukin RS (1991). Neuroanatomical localization of kappa-1 and kappa-2 opioid receptors in rat and guinea-pig brain. Brain Res 562: 57-65.
67. Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol Rev 94: 469-492.
68. Yan F, Roth BL (2004). Salvinorin A: a novel and highly selective kappa opioid receptor agonist. Life Sci 75: 2615-2619.
69. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179: 551-558.